p53 is frequently mutated in Burkitt's lymphoma cell lines.
about
Evidence that dynamin-2 functions as a signal-transducing GTPaseEpstein-Barr virus and Burkitt lymphomaModulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcriptionOncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.Biology and disease associations of Epstein-Barr virus.Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2ARac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-κB hyperactivation.Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expressionThe Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.Paediatric orofacial tumours: new oral health concern in paediatric patientsEpstein-barr virus-induced changes in B-lymphocyte gene expression.Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replicationp53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer.Molecular genetic analysis of Epstein-Barr virus Cp promoter functionEpstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions.Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins.Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramThe cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuliLoss of functional pRB is not a ubiquitous feature of B-cell malignanciesTransforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas.Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes.Alterations of the p53 gene in nasopharyngeal carcinoma.Non-conservative homologous recombination in human B lymphocytes is promoted by activation-induced cytidine deaminase and transcription.An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.APC2 and Axin promote mitotic fidelity by facilitating centrosome separation and cytoskeletal regulationEpstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
P2860
Q4215980-A71CF1D6-0CF7-4EC5-B1B0-303F9058D9A8Q50348210-650F8ED0-D9F4-448D-80D7-CA0FE82B305AQ54749080-8F6B6384-9618-4BF6-A869-3EABF385AA32Q54797121-AE845349-2CCF-41AF-BB85-9F026EB208DBQ54797136-8D3AC152-F081-414E-834E-7A340CA8E134Q54797148-77E5CAC7-2211-48BC-94FB-0A6AF84075F1Q54797153-CDAA316F-05B3-4A41-84E3-A296AF9DF8F8Q54797155-0B874DAC-63FB-43FB-9329-3784B1BEB9C8Q54898929-4AFF83D6-C356-4CCF-AAAE-C7120AB87B5BQ54902893-3E74BF06-4AE4-4E97-B4CC-0E7702088D10Q54907447-B1BBE2D5-F640-4DE8-9591-B31B4C6E0928Q54937282-17858624-39CA-477D-B603-F0817217473CQ54949198-8588258B-3149-4A18-A684-B8A592AF2EBF
P1343
Q22254607-3084D71F-3AD0-495D-B563-1AE2BE188565Q24669890-EF762941-3AF1-4250-B13F-34261B5EFCC8Q24811971-BB401965-5782-4636-B10C-C78731EC80ABQ28187745-BE84DFCF-1113-4E1D-9264-2D8046C61648Q33713735-351E5748-444E-4431-BB8C-E13F4537CEE1Q33716529-849D87D3-5E07-4066-AE3F-DBBE96BA1719Q33772230-7D61E2AC-061E-4DDD-B711-2ED03C4DE2B6Q33794029-17F65FD8-7215-48D5-A08A-FD34CFE40270Q33806023-78322862-DD5F-4D01-956D-0FC73ECA482CQ33938457-8EC9E099-134D-4F57-960C-F33E9AC168AFQ33955300-78BF266C-1149-470F-B3F7-0CA1FC64A161Q34039568-50FA1B84-8FE6-491C-A390-CE69920C21FBQ34045809-E6818DF3-B571-4E97-81C2-A89B3394CDA0Q34103135-A7C52539-65B5-44FF-8BE3-3712CF0F56CDQ34267599-8F31260E-D111-4335-B992-FCADD8F0DC6DQ34336239-8AE34463-C2AD-4BC7-A6B2-760499CB4335Q34347958-40D75EE9-8D5B-4414-B5BC-413566492BD9Q34553293-D8EA1B71-971C-4375-8CD3-A189FB821891Q34972350-72A142F2-E918-41ED-9D16-059C0E3538AFQ35856784-7AFC201B-4898-4450-8478-6FC8D77AC1F5Q35873657-2C4D3889-4138-4D9F-844E-5410EC605AEFQ36016499-94470351-0EF2-4236-A257-9CAF88C6C062Q36023151-E171B0AD-E444-4B4F-813A-57B2F140BAC5Q36202253-C6BD106D-4BE5-4D99-8432-4BB0911CCD13Q36358319-1B7ECA8D-814B-4E15-9C87-089936672A2BQ36392660-828B2BAE-8FAC-4FD3-9091-3BB5EA36470AQ36414572-420F6C03-3260-4EE1-AE98-3AEB4979233AQ36617740-D9A63DAF-4465-4DB1-AF72-535C0A3A4EF4Q36620902-1E4F2EB9-4647-40E7-8FAB-0082BAF6FB38Q36628203-266131AD-A371-4A85-AE5D-DD99C94D02E3Q36648185-36D09B25-FB7C-40B4-8EDC-518D13EC917EQ36671026-86CE4557-1C37-43DC-A0E5-88528652C9ADQ36678903-95A88638-4F5F-400F-B7FB-7DBF462765F5Q36684233-5BA48282-EE12-4038-AAAE-2EECDB30AEA1Q36698270-49703F2B-3EC2-42C6-9344-A68CD1A938C0Q36909318-046DD90C-0510-4285-B9EC-5350A584BC3BQ37111674-4E8B62E8-B00D-4237-8BFB-EC7E7DC4B666Q37209158-612F4F73-6875-4743-9ECD-6CCA9A299204Q37394390-BF091CC1-97FE-4548-80F1-5628B6B29D45Q37488736-AC461115-3BF1-4DE0-8D7B-61E5C0D2C8A7
P2860
p53 is frequently mutated in Burkitt's lymphoma cell lines.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
p53 is frequently mutated in Burkitt's lymphoma cell lines.
@en
type
label
p53 is frequently mutated in Burkitt's lymphoma cell lines.
@en
prefLabel
p53 is frequently mutated in Burkitt's lymphoma cell lines.
@en
P2093
P2860
P4510
P1433
P1476
p53 is frequently mutated in Burkitt's lymphoma cell lines.
@en
P2093
P2860
P304
P407
P577
1991-10-01T00:00:00Z